Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout.

Yeonghee EunHeewon HanKyunga KimSeonyoung KangSeulkee LeeHyungjin KimJaejoon LeeEun-Mi KohHoon Suk Cha

Published in: Therapeutic advances in musculoskeletal disease (2022)

In this study, significant difference was not found in CV risk between allopurinol and benzbromarone initiators. In the high-CV-risk group, the incidence of CV events did not differ between allopurinol and benzbromarone initiators.

Keyphrases

metabolic syndrome